Obesity is a status with a body weight that is grossly above the recommended standards, usually due to accumulation of excess fats in the body . In the body mass index, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese .

The goal of obesity management is to improve health, and sustained weight loss of more than 10% overall bodyweight improves many of the complications associated with obesity . In conjunction with lifestyle interventions, anti-obesity medications and bariatric surgery improve the maintenance of weight loss and associated health gains . These highly effective anti-obesity medications are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants . Furthermore, semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction .

Prevention & Lipids

Obesity

Obesity as a cardiovascular risk state: incretin therapies (semaglutide, tirzepatide), weight-loss outcome trials, and cardiometabolic risk.

Also called adiposity, weight management, anti-obesity medication

Sources: 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

Obesity is a status with a body weight that is grossly above the recommended standards, usually due to accumulation of excess fats in the body.1

Treatment

The goal of obesity management is to improve health, and sustained weight loss of more than 10% overall bodyweight improves many of the complications associated with obesity.1 In conjunction with lifestyle interventions, anti-obesity medications and bariatric surgery improve the maintenance of weight loss and associated health gains.1 These highly effective anti-obesity medications are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants.1 Furthermore, semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction.2

FDA actions

FDA approvals, label changes, device decisions and recalls on Obesity from the last three months.

FDA new indicationAug 27, 2026

FDA new indication: Mounjaro (Tirzepatide)

Manufacturer: Eli Lilly and Company. Submission type: SUPPL. Route: SUBCUTANEOUS. Form: SOLUTION

Efficacy supplement (new indication or population) — Efficacy
Tirzepatide is a GIP/GLP-1 receptor agonist
FDA action date Aug 27, 2026
Form: Solution Subcutaneous

TIRZEPATIDEMOUNJAROtirzepatide

FDA

FDA new indicationAug 26, 2026

FDA new indication: Zepbound (Tirzepatide)

Manufacturer: Eli Lilly and Company. Submission type: SUPPL. Route: SUBCUTANEOUS. Form: SOLUTION

Efficacy supplement (new indication or population) — Efficacy
Tirzepatide is a GIP/GLP-1 receptor agonist
FDA action date Aug 26, 2026
Form: Solution Subcutaneous

TIRZEPATIDEZEPBOUNDtirzepatide

FDA

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.